All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
NICE to make daratumumab, bortezomib and dexamethasone triplet available in England via the cancer drugs fund
It has been announced today, 12 February, 2019, that the National Institute for Health and Care Excellence (NICE), will make the triplet regimen; daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone (DVd), available to patients with multiple myeloma (MM) in England through the Cancer Drugs Fund (CDF). Patients will be eligible to receive DVd if they have already received one prior line of therapy. The triplet regimen will not, however, be routinely available until the long-term survival benefit can be supported by further data and re-evaluated by NICE.1
Background
Daratumumab is an anti-CD38 monoclonal antibody, bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid. This triplet combination was compared to bortezomib-dexamethasone (Vd) alone in the phase III CASTOR trial (NCT02136134).2
Data given as DVd versus Vd
- Multi-center, open-label, randomized, active-controlled, phase III study
- Patients with relapsed/refractory MM
- Patients were randomized 1:1 to DVd or Vd (N = 498):
- DVd (n = 251)
- Vd (n = 247)
- Median follow-up: 19.4 months (0–27.7)
- Progression-free survival (PFS): 16.7 vs 7.1 months (HR: 0.31, 95% CI, 0.24–0.39, P < 0.0001)
- Overall response rate: 83.8% vs 63.2% (P < 0.0001)
- PFS survival benefit was most prominent in patients who had received 1 prior line of therapy
- DVd was superior in all subgroups, including:
- Prior treatment exposure
- Lenalidomide-refractory status
- Time since last therapy
- Cytogenetic risk
- Minimal residual disease-negative rates were >2.5x higher in the DVd arm across subgroups
- At the longer follow-up, DVd also maintained the reported safety profile
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?